Neurocrine Shares Rise as New NBI‑567 Alzheimer’s Trial Kicks Off
Neurocrine Biosciences’ NBIX stock hits a new intraday high, while its Phase 2 NBI‑567 trial opens fresh hope for Alzheimer’s treatment.
- NEUROCRINE BIOSCIENCES INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read